dexmethylphenidate
Phase 3- Indications
- Attention Deficit/Hyperactivity Disorder
Company intelligence / Profile preview
ChemWerth
Woodbridge, Connecticut, United Stateschemwerth.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
- Therapeutic areas
- Other
- Modalities
- Active Pharmaceutical Ingredients (APIs)including corticosteroid products[3]
- Industry
- Contract Manufacturing Organization
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Manufacturing partnerships with companies including Tianjin Tianyao Pharmaceuticals Co., Ltd.[3]and serves as regulatory agent for 25+ FDA-approved facilities in the US, Europe, India, and China[5]
Beyond the preview
Go deeper on ChemWerth.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChemWerth.